Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)Jeff P. Sharman, David Andorsky, Yang Bai et al.|Blood|2022Cited by 3
Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.David Andorsky, Jeff P. Sharman, Ralph V. Boccia et al.|Journal of Clinical Oncology|2024Cited by 2